Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Of Price And Premiums: Medicare Has Put Alzheimer’s Drug Sponsors On Notice

Executive Summary

Medicare will be closely watching for pricing decisions by Eli Lilly, Eisai and Roche once the companies gain US marketing approval for their amyloid-directed monoclonal antibody drugs for Alzheimer’s disease.

You may also be interested in...



Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC

Medicaid advisory panel members suggest states should have the same flexibility as Medicare to adopt coverage with evidence development requirements for drugs with limited supporting evidence.

Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches

But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.

Lilly Phase III Alzheimer’s Data Will Set Stage For Unrestricted Medicare Coverage Request

Donanemab results due next year have a good chance of persuading CMS to offer unrestricted coverage, Lilly argues, even though the drug might just have accelerated approval at that point. ‘We believe that having two positive pivotal trials should meet that high level of evidence.’

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel